The U.S. Food and Drug Administration Approves First Eye Drop for Treating Age-Related Farsightedness

The U.S. Food and Drug Administration (FDA) has approved the launch of the first prescription eye drop for treating age-related farsightedness, a common condition that weakens the ability to see close up.

The new drop is called "Vizz" and contains the ingredient "asicyclidine" which improves near vision with a single daily dose, lasting up to 10 hours, reducing reliance on reading glasses.

Vizz distinguishes itself from previous drops that negatively affected distance vision and caused side effects such as heavy eyebrows, as it selectively works to constrict the pupil only, making it more comfortable and effective.

The approval came after three randomized clinical trials involving hundreds of participants and over 30,000 days of use, with no serious side effects reported.

Vizz is considered a promising treatment option for millions suffering from this visual problem, as it may allow them to forgo glasses or corrective lenses.

The drop is expected to be available in U.S. pharmacies by the end of 2025, and only with a prescription.

This approval represents an important advancement in the treatment of age-related vision problems, opening the door to more accessible pharmaceutical solutions compared to traditional methods.